Stay updated on Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    Locations entries were reorganized: per-state location items were removed and replaced with consolidated regional listings, and a new revision tag v3.3.3 was added.
    Difference
    0.8%
    Check dated 2025-12-21T21:16:56.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    Revision tag updated from v3.3.1 to v3.3.2 appears on the page; no changes to study details, eligibility criteria, endpoints, or locations were observed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-30T04:57:48.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Publication description in the Publications From PubMed section was updated to read: 'These publications are automatically filled in from PubMed, a public database of scientific and medical articles, and may or may not be about the study.' The previous wording describing PubMed publications was replaced.
    Difference
    0.0%
    Check dated 2025-11-23T00:48:41.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    - Added Tainan, Taiwan, 70403 and removed Tainan City, Taiwan, 70403 from the study locations.
    Difference
    0.1%
    Check dated 2025-11-15T16:57:33.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    In Publications, the Meng et al. cost-effectiveness article is updated from an online ahead-of-print Oct 2025 version to the final December 2025 publication (J Med Econ).
    Difference
    0.0%
    Check dated 2025-11-08T13:08:33.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    Added a new scholarly citation on cost-effectiveness of enfortumab vedotin plus pembrolizumab for urothelial carcinoma, expanding the page's references with an authoritative source. No deletions were reported.
    Difference
    0.8%
    Check dated 2025-10-10T16:52:56.000Z thumbnail image

Stay in the know with updates to Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.